Akums Unveils Ripasudil+timolol Combo for Glaucoma, Ocular Hypertension

Akums Drugs & Pharmaceuticals has announced the launch of a pioneering ripasudil+timolol combination therapy for glaucoma treatment. The DCGI-approved product represents a significant advancement in ophthalmic care, with Akums becoming the first Indian CDMO (contract development manufacturing organisation) to receive approval for this innovative formulation.
 
Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5% of the global burden. The condition remains third among causes of vision impairment in India, after cataract and refractive errors. Also, Ocular hypertension is closely linked to glaucoma, many eye care professionals consider ocular hypertension to be a precursor or warning sign for glaucoma. Ocular hypertension refers to elevated pressure within the eye (intraocular pressure or IOP) that is higher than normal but without detectable damage to the optic nerve or visual field loss that would indicate glaucoma. While not everyone with ocular hypertension develops glaucoma, regular monitoring is crucial. Managing both conditions primarily involves lowering intraocular pressure to prevent further complications.
 
The new combination therapy offers a dual mechanism of action for superior intraocular pressure (IOP) control: Ripasudil enhances aqueous humour outflow through the trabecular meshwork, while timolol reduces aqueous humour production. This synergistic approach delivers more substantial and sustained IOP reduction compared to single-drug treatments.
 
Sanjeev Jain, managing director, Akums Drugs & Pharmaceuticals,  said, ""This innovation integrates two distinct mechanisms of action to improve glaucoma treatment. By enhancing efficacy and ease of use, we aim to offer a more practical and patient-friendly solution. Our focus is on better clinical outcomes, reducing disease progression, and ultimately improving the quality of life for those affected. With a patient-first approach and a commitment to Make in India, we continue to develop solutions that are of high-quality, and aligned with global standards.
 
The single combination drop formulation significantly simplifies treatment regimens, addressing a major challenge in glaucoma management—patient adherence. By combining two medications into one product, patients benefit from enhanced convenience and potentially improved compliance, he added.
 
""With the rising prevalence of glaucoma in India, introducing therapies that enhance efficacy and patient compliance is crucial. This launch marks a significant step in making high-quality and effective treatment more accessible,"" said Sandeep Jain, managing director,  Akums Drugs & Pharmaceuticals.
 
Akums will utilize its state-of-the-art manufacturing facilities to ensure consistent supply and broad availability of this breakthrough therapy. With approximately 11.9 million people affected by glaucoma in India, this innovative combination addresses a critical healthcare need by providing an effective solution that simplifies treatment while potentially improving outcomes, said the company.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!